Melanoma-associated antigen 10 (MAGE-A10) peptide GLYDGMEHL presented by HLA-A*02:01 or HLA-A*02:06 (MAGE-A10/HLA-A*02)

Melanoma-associated antigen 10 (MAGE-A10) is a member of the cancer-testis antigen family, which is characterized by restricted expression in immune-privileged germ cells and aberrant overexpression in various malignancies [1][3]. The specific nonamer peptide GLYDGMEHL (residues 254-262) is processed intracellularly and presented on the cell surface by Human Leukocyte Antigen (HLA) alleles A*02:01 and A*02:06 [2][4]. This peptide-MHC complex serves as a highly specific target for adoptive immunotherapy, as it is absent from healthy somatic tissues [4]. Therapeutic agents like ADP-A2M10 utilize affinity-enhanced T-cell receptors (TCRs) to bind this complex, triggering a potent cytotoxic immune response against tumor cells [2][5]. Clinical development has focused on treating advanced solid tumors, including lung and bladder cancers, where MAGE-A10 expression is prevalent [5]. The primary challenge in targeting this complex is ensuring the TCR does not cross-react with similar peptides found in vital organs [4].

Other names

MAGE-A10(254-262) peptideGLYDGMEHL-HLA-A*02 complexMAGEA10-001MAGE-A10 antigen

T-cell receptor (TCR) engineered T-cell therapy designed to recognize the specific peptide-MHC complex and induce cytotoxic lysis of tumor cells.